The most important therapeutic effect of cholinesterase inhibitors (ChEI) on approximately
50% of Alzheimer's disease (AD) patients is to stabilize cognitive function at a steady level …

An important aspect of brain cholinesterase function is related to enzymatic differences. The
brain of mammals contains two major forms of cholinesterases: acetylcholinesterase (AChE) …

The brain of mammals contains two major forms of cholinesterases (ChEs):
acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). The two forms differ …

During the last decade, a systematic effort to develop a pharmacological treatment for
Alzheimer disease (AD) resulted into three drugs being registered for the first time in USA …

Background: Butyrylcholinesterase (BChE), also known as the “pseudo” or “non-neuronal”
cholinesterase, is traditionally thought to have a restricted CNS distribution and to play little …

Butyrylcholinesterase is a serine hydrolase biochemically related to the cholinergic enzyme
acetylcholinesterase. It is capable of hydrolyzing esters of choline. Butyrylcholinesterase has …

The cholinergic hypothesis of decline in dementia, whereby deficits in learning, memory and
behavior are caused, at least in part, by decreased levels of acetylcholine (ACh) in the brain …

A consensus exists that cholinesterase inhibitors (ChEIs) are efficacious for mild to moderate
Alzheimer's Disease (AD). Unfortunately, the number of non-responders is large and the …

The cholinesterases are members of the serine hydrolase family, which utilizes a serine
residue at the active site. Acetylcholinesterase (AChE) is distinguished from …

Inhibitors of the enzyme acetylcholinesterase (AChE) are presently used as long-term
symptomatic treatments for patients with Alzheimer disease (AD), as they enhance central …